PHAXIAM Therapeutics S.A. (PHXM.PA)
EUR 0.68
(-3.66%)
EUR 0.68
(-3.66%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -5.00 EUR | -7263.77% |
| 2022 | -0.07 EUR | 99.68% |
| 2021 | -20.99 EUR | 43.04% |
| 2020 | -36.85 EUR | -14.12% |
| 2019 | -32.29 EUR | -63.91% |
| 2018 | -19.70 EUR | 27.71% |
| 2017 | -27.25 EUR | -6.95% |
| 2016 | -25.48 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.88 EUR | 10.84% |
| 2024 Q1 | -0.99 EUR | -7.28% |
| 2023 Q3 | -1.15 EUR | 61.28% |
| 2023 Q1 | -1.86 EUR | -875.0% |
| 2023 FY | - EUR | -6704.12% |
| 2023 Q4 | -0.92 EUR | 20.0% |
| 2023 Q2 | -2.97 EUR | -59.68% |
| 2022 Q2 | -0.31 EUR | 0.0% |
| 2022 Q4 | 0.24 EUR | 115.69% |
| 2022 Q3 | -1.53 EUR | -393.55% |
| 2022 FY | - EUR | 99.68% |
| 2021 Q2 | -11.31 EUR | 0.0% |
| 2021 Q4 | -7.70 EUR | 0.0% |
| 2021 FY | - EUR | 43.04% |
| 2020 Q4 | -18.84 EUR | 0.0% |
| 2020 FY | - EUR | -14.12% |
| 2020 Q2 | -18.01 EUR | 0.0% |
| 2019 Q4 | -17.20 EUR | 0.0% |
| 2019 FY | - EUR | -63.91% |
| 2018 FY | - EUR | 27.71% |
| 2017 FY | - EUR | -6.95% |
| 2016 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Nicox S.A. | -0.42 EUR | -1090.476% |
| European Medical Solutions | -0.00 EUR | -999900.0% |
| FERMENTALG | -0.32 EUR | -1462.5% |
| argenx SE | -4.67 EUR | -7.066% |
| BioSenic S.A. | -0.21 EUR | -2280.952% |
| Celyad Oncology SA | -0.33 EUR | -1415.152% |
| Hyloris Pharmaceuticals SA | -0.55 EUR | -809.091% |
| Onward Medical N.V. | -1.20 EUR | -316.667% |
| Oxurion NV | -0.01 EUR | -43378.261% |
| Financière de Tubize SA | 1.98 EUR | 352.525% |
| UCB SA | 1.81 EUR | 376.243% |